Several other research analysts have also weighed in on the stock. Morgan Stanley boosted their price objective on shares of Eli Lilly and from $364.00 to $369.00 in a research note on Friday, April 29th. Mizuho boosted their target price on Eli Lilly and from $315.00 to $356.00 in a report on Monday, May 2nd. Daiwa Capital Markets initiated coverage on Eli Lilly and in a research note on Thursday, March 10th. They issued an “outperform” rating and a $286.00 price target on the stock. Wells Fargo & Company lifted their price objective on shares of Eli Lilly and from $280.00 to $305.00 in a research report on Friday, April 29th. Finally, The Goldman Sachs Group increased their price objective on shares of Eli Lilly and from $234.00 to $264.00 and gave the company a “neutral” rating in a research report on Tuesday, April 12th. One analyst has rated the stock with a sell rating, three have issued a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $304.58.
NYSE LLY traded up $1.05 during trading hours on Wednesday, hitting $307.01. 3,192,382 shares of the company traded hands, compared to its average volume of 2,931,045. The company has a debt-to-equity ratio of 1.60, a quick ratio of 0.98 and a current ratio of 1.27. The business’s 50-day moving average is $293.92 and its 200-day moving average is $268.67. The stock has a market capitalization of $291.71 billion, a price-to-earnings ratio of 45.48, a P/E/G ratio of 2.27 and a beta of 0.40. Eli Lilly and has a twelve month low of $195.50 and a twelve month high of $314.00.
In related news, CAO Donald A. Zakrowski sold 1,660 shares of Eli Lilly and stock in a transaction that occurred on Friday, February 25th. The shares were sold at an average price of $243.84, for a total value of $404,774.40. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Marschall S. Runge acquired 202 shares of the stock in a transaction on Tuesday, March 1st. The shares were purchased at an average price of $246.78 per share, with a total value of $49,849.56. The disclosure for this purchase can be found here. Insiders sold a total of 1,287,868 shares of company stock valued at $368,331,582 over the last ninety days. Insiders own 0.12% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in LLY. Fortitude Advisory Group L.L.C. grew its position in Eli Lilly and by 25.1% in the first quarter. Fortitude Advisory Group L.L.C. now owns 1,970 shares of the company’s stock valued at $564,000 after acquiring an additional 395 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Eli Lilly and by 40.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 3,385 shares of the company’s stock valued at $970,000 after purchasing an additional 974 shares in the last quarter. First National Bank of Omaha grew its holdings in shares of Eli Lilly and by 7.5% during the 1st quarter. First National Bank of Omaha now owns 52,758 shares of the company’s stock valued at $15,108,000 after purchasing an additional 3,698 shares during the last quarter. M Holdings Securities Inc. acquired a new position in Eli Lilly and during the 1st quarter worth approximately $755,000. Finally, Cantor Fitzgerald L. P. bought a new position in Eli Lilly and in the 1st quarter valued at approximately $623,000. 82.75% of the stock is currently owned by institutional investors and hedge funds.
About Eli Lilly and (Get Rating)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
- Get a free copy of the StockNews.com research report on Eli Lilly and (LLY)
- Short-Covering Begins In Big Lots
- Agilent Technologies Is Bottoming But Don’t Buy It Yet
- Institutions Ring The Register On Toll Brothers Stock
- Dick’s Sporting Goods Falls Flat On Weak Guidance
- It’s Time to Buy into Planet Fitness Stock
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.